Effects of methyltestosterone on insulin secretion and sensitivity in women

Michael P. Diamond, David Grainger, Meredith C. Diamond, Robert S. Sherwin, Ralph A Defronzo

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The frequent coexistence of hyperandrogenism and insulin resistance is well established; however, whether a cause and effect relationship exists remains to be established. In this study we tested the hypothesis that short- term androgen administered to women would induce insulin resistance. To test this hypothesis, regularly menstruating, nonobese women were studied before and during methyltestosterone administration (5 mg tid for 10-12 days) by the hyperglycemic (n = 8) and euglycemic, hyperinsulinemic (n = 7) clamp techniques. Short-term methyltestosterone administration had no significant effects on the fasting levels of glucose, insulin, c-peptide, glucagon, or glucose turnover. During the hyperglycemic clamp studies, the mean glucose level during the final hour was 203 ± 2 and 201 ± 1 mg/dL in the methyltestosterone and control studies, respectively. The insulin response to this hyperglycemic challenge was slightly but not significantly greater during methyltestosterone treatment (first phase 59 ± 8 vs. 50 ± 8 μU/mL in controls; second phase 74 ± 9 vs. 67 ± 9 μU/mL in controls; total insulin response 133 ± 16 vs. 117 ± 15 μU/mL in controls). In spite of this, glucose uptake was reduced from the control study value of 10.96 ± 1.11 to 7.3 ± 0.70 mg/kg/min by methyltestosterone (P < 0.05). The ratio of glucose uptake per unit of insulin was also significantly reduced from a control study value of 14.3 ± 1.4 to 9.4 ± 1.3 mg/kg/min per μU/mL x 100 during methyltestosterone administration. In the euglycemic hyperinsulinemic clamp studies, insulin was infused at rates of 0.25 and 1.0 mU/kg/min to achieve insulin levels of approximately 25 and 68 μU/mL, respectively. During low-dose insulin infusion, rates of endogenous hepatic glucose production were equivalently suppressed from basal values of 2.37 ± 0.29 and 2.40 ± 0.27 mg/kg/min to 0.88 ± 0.25 and 0.77 ± 0.26 mg/kg/min in the methyltestesterone and control studies respectively. Whole body glucose uptake during low-dose insulin infusion was minimally affected. During the high-dose insulin infusion, endogenous hepatic glucose production was nearly totally suppressed in both groups. However, whole body glucose uptake was reduced from the control value of 6.11 ± 0.49 mg/kg/min to 4.93 ± 0.44 mg/kg/min during methyltestosterone administration (P < 0.05). Our data demonstrate that androgen excess leads to the develop merit of insulin resistance during both hyperglycemic and euglycemic hyperinsulinemia. These findings provide direct evidence for a relationship between hyperandrogenemia and insulin resistance, and its associated risk factors for cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)4420-4425
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume83
Issue number12
StatePublished - 1998

Fingerprint

Methyltestosterone
Insulin Resistance
Insulin
Glucose
Clamping devices
Androgens
Hyperandrogenism
Glucose Clamp Technique
Liver
Hyperinsulinism
Glucagon
Fasting
Cardiovascular Diseases

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of methyltestosterone on insulin secretion and sensitivity in women. / Diamond, Michael P.; Grainger, David; Diamond, Meredith C.; Sherwin, Robert S.; Defronzo, Ralph A.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 83, No. 12, 1998, p. 4420-4425.

Research output: Contribution to journalArticle

Diamond, MP, Grainger, D, Diamond, MC, Sherwin, RS & Defronzo, RA 1998, 'Effects of methyltestosterone on insulin secretion and sensitivity in women', Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 12, pp. 4420-4425.
Diamond, Michael P. ; Grainger, David ; Diamond, Meredith C. ; Sherwin, Robert S. ; Defronzo, Ralph A. / Effects of methyltestosterone on insulin secretion and sensitivity in women. In: Journal of Clinical Endocrinology and Metabolism. 1998 ; Vol. 83, No. 12. pp. 4420-4425.
@article{f48a6ba476ce4918ab85391c428a3c0e,
title = "Effects of methyltestosterone on insulin secretion and sensitivity in women",
abstract = "The frequent coexistence of hyperandrogenism and insulin resistance is well established; however, whether a cause and effect relationship exists remains to be established. In this study we tested the hypothesis that short- term androgen administered to women would induce insulin resistance. To test this hypothesis, regularly menstruating, nonobese women were studied before and during methyltestosterone administration (5 mg tid for 10-12 days) by the hyperglycemic (n = 8) and euglycemic, hyperinsulinemic (n = 7) clamp techniques. Short-term methyltestosterone administration had no significant effects on the fasting levels of glucose, insulin, c-peptide, glucagon, or glucose turnover. During the hyperglycemic clamp studies, the mean glucose level during the final hour was 203 ± 2 and 201 ± 1 mg/dL in the methyltestosterone and control studies, respectively. The insulin response to this hyperglycemic challenge was slightly but not significantly greater during methyltestosterone treatment (first phase 59 ± 8 vs. 50 ± 8 μU/mL in controls; second phase 74 ± 9 vs. 67 ± 9 μU/mL in controls; total insulin response 133 ± 16 vs. 117 ± 15 μU/mL in controls). In spite of this, glucose uptake was reduced from the control study value of 10.96 ± 1.11 to 7.3 ± 0.70 mg/kg/min by methyltestosterone (P < 0.05). The ratio of glucose uptake per unit of insulin was also significantly reduced from a control study value of 14.3 ± 1.4 to 9.4 ± 1.3 mg/kg/min per μU/mL x 100 during methyltestosterone administration. In the euglycemic hyperinsulinemic clamp studies, insulin was infused at rates of 0.25 and 1.0 mU/kg/min to achieve insulin levels of approximately 25 and 68 μU/mL, respectively. During low-dose insulin infusion, rates of endogenous hepatic glucose production were equivalently suppressed from basal values of 2.37 ± 0.29 and 2.40 ± 0.27 mg/kg/min to 0.88 ± 0.25 and 0.77 ± 0.26 mg/kg/min in the methyltestesterone and control studies respectively. Whole body glucose uptake during low-dose insulin infusion was minimally affected. During the high-dose insulin infusion, endogenous hepatic glucose production was nearly totally suppressed in both groups. However, whole body glucose uptake was reduced from the control value of 6.11 ± 0.49 mg/kg/min to 4.93 ± 0.44 mg/kg/min during methyltestosterone administration (P < 0.05). Our data demonstrate that androgen excess leads to the develop merit of insulin resistance during both hyperglycemic and euglycemic hyperinsulinemia. These findings provide direct evidence for a relationship between hyperandrogenemia and insulin resistance, and its associated risk factors for cardiovascular disease.",
author = "Diamond, {Michael P.} and David Grainger and Diamond, {Meredith C.} and Sherwin, {Robert S.} and Defronzo, {Ralph A}",
year = "1998",
language = "English (US)",
volume = "83",
pages = "4420--4425",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - Effects of methyltestosterone on insulin secretion and sensitivity in women

AU - Diamond, Michael P.

AU - Grainger, David

AU - Diamond, Meredith C.

AU - Sherwin, Robert S.

AU - Defronzo, Ralph A

PY - 1998

Y1 - 1998

N2 - The frequent coexistence of hyperandrogenism and insulin resistance is well established; however, whether a cause and effect relationship exists remains to be established. In this study we tested the hypothesis that short- term androgen administered to women would induce insulin resistance. To test this hypothesis, regularly menstruating, nonobese women were studied before and during methyltestosterone administration (5 mg tid for 10-12 days) by the hyperglycemic (n = 8) and euglycemic, hyperinsulinemic (n = 7) clamp techniques. Short-term methyltestosterone administration had no significant effects on the fasting levels of glucose, insulin, c-peptide, glucagon, or glucose turnover. During the hyperglycemic clamp studies, the mean glucose level during the final hour was 203 ± 2 and 201 ± 1 mg/dL in the methyltestosterone and control studies, respectively. The insulin response to this hyperglycemic challenge was slightly but not significantly greater during methyltestosterone treatment (first phase 59 ± 8 vs. 50 ± 8 μU/mL in controls; second phase 74 ± 9 vs. 67 ± 9 μU/mL in controls; total insulin response 133 ± 16 vs. 117 ± 15 μU/mL in controls). In spite of this, glucose uptake was reduced from the control study value of 10.96 ± 1.11 to 7.3 ± 0.70 mg/kg/min by methyltestosterone (P < 0.05). The ratio of glucose uptake per unit of insulin was also significantly reduced from a control study value of 14.3 ± 1.4 to 9.4 ± 1.3 mg/kg/min per μU/mL x 100 during methyltestosterone administration. In the euglycemic hyperinsulinemic clamp studies, insulin was infused at rates of 0.25 and 1.0 mU/kg/min to achieve insulin levels of approximately 25 and 68 μU/mL, respectively. During low-dose insulin infusion, rates of endogenous hepatic glucose production were equivalently suppressed from basal values of 2.37 ± 0.29 and 2.40 ± 0.27 mg/kg/min to 0.88 ± 0.25 and 0.77 ± 0.26 mg/kg/min in the methyltestesterone and control studies respectively. Whole body glucose uptake during low-dose insulin infusion was minimally affected. During the high-dose insulin infusion, endogenous hepatic glucose production was nearly totally suppressed in both groups. However, whole body glucose uptake was reduced from the control value of 6.11 ± 0.49 mg/kg/min to 4.93 ± 0.44 mg/kg/min during methyltestosterone administration (P < 0.05). Our data demonstrate that androgen excess leads to the develop merit of insulin resistance during both hyperglycemic and euglycemic hyperinsulinemia. These findings provide direct evidence for a relationship between hyperandrogenemia and insulin resistance, and its associated risk factors for cardiovascular disease.

AB - The frequent coexistence of hyperandrogenism and insulin resistance is well established; however, whether a cause and effect relationship exists remains to be established. In this study we tested the hypothesis that short- term androgen administered to women would induce insulin resistance. To test this hypothesis, regularly menstruating, nonobese women were studied before and during methyltestosterone administration (5 mg tid for 10-12 days) by the hyperglycemic (n = 8) and euglycemic, hyperinsulinemic (n = 7) clamp techniques. Short-term methyltestosterone administration had no significant effects on the fasting levels of glucose, insulin, c-peptide, glucagon, or glucose turnover. During the hyperglycemic clamp studies, the mean glucose level during the final hour was 203 ± 2 and 201 ± 1 mg/dL in the methyltestosterone and control studies, respectively. The insulin response to this hyperglycemic challenge was slightly but not significantly greater during methyltestosterone treatment (first phase 59 ± 8 vs. 50 ± 8 μU/mL in controls; second phase 74 ± 9 vs. 67 ± 9 μU/mL in controls; total insulin response 133 ± 16 vs. 117 ± 15 μU/mL in controls). In spite of this, glucose uptake was reduced from the control study value of 10.96 ± 1.11 to 7.3 ± 0.70 mg/kg/min by methyltestosterone (P < 0.05). The ratio of glucose uptake per unit of insulin was also significantly reduced from a control study value of 14.3 ± 1.4 to 9.4 ± 1.3 mg/kg/min per μU/mL x 100 during methyltestosterone administration. In the euglycemic hyperinsulinemic clamp studies, insulin was infused at rates of 0.25 and 1.0 mU/kg/min to achieve insulin levels of approximately 25 and 68 μU/mL, respectively. During low-dose insulin infusion, rates of endogenous hepatic glucose production were equivalently suppressed from basal values of 2.37 ± 0.29 and 2.40 ± 0.27 mg/kg/min to 0.88 ± 0.25 and 0.77 ± 0.26 mg/kg/min in the methyltestesterone and control studies respectively. Whole body glucose uptake during low-dose insulin infusion was minimally affected. During the high-dose insulin infusion, endogenous hepatic glucose production was nearly totally suppressed in both groups. However, whole body glucose uptake was reduced from the control value of 6.11 ± 0.49 mg/kg/min to 4.93 ± 0.44 mg/kg/min during methyltestosterone administration (P < 0.05). Our data demonstrate that androgen excess leads to the develop merit of insulin resistance during both hyperglycemic and euglycemic hyperinsulinemia. These findings provide direct evidence for a relationship between hyperandrogenemia and insulin resistance, and its associated risk factors for cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=0141881946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141881946&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 4420

EP - 4425

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -